Introduction
The Drug Master File (DMF) is one of the key documents for drug registration in international markets, containing confidential and detailed information about the production, control, quality and stability of the active pharmaceutical ingredient (API). This document plays an important role in ensuring the quality of the drug and facilitating the registration and evaluation process by regulatory agencies such as the FDA, EMA and WHO. This article discusses the principles and steps of preparing a DMF for APIs.
1. Definition and importance of DMF
A DMF is a non-mandatory but strategic document that provides comprehensive information about an API to regulatory agencies. Companies can provide this information to regulatory agencies without disclosing details to the final drug applicants. This helps protect the intellectual property of manufacturers.
2. Types of DMF in FDA
The FDA has defined five types of DMF:
- Type I (Production Information): No longer used.
- Type II: Information about API, ready-to-use drug product or excipients
- Type III: Information about packaging materials
- Type IV: Information about submission and quality control methods
- Type V: Specific reference information with FDA approval
For API, the focus is mainly on Type II.
3. Proposed DMF structure
The DMF must be prepared according to the CTD format, which consists of five modules, but for APIs, modules 1, 2, and 3 are usually used:
- Module 1: Administrative information
- Cover letter, forms, contact information
- Module 2: Quality of Service (QOS) Summary
- Summary of quality information available in Module 3
- Module 3: Quality (Quality/CMC)
- Comprehensive information on raw materials, specifications, synthesis methods, in-process controls, stability and validation of analytical methods
4. Key requirements in preparing Module 3
- S (Substance): Information about the API, including:
- Chemical, physical and biological characteristics
- Synthesis route, starting materials and reagents
- Quality control of raw materials and solvents
- Validation of analytical methods
- Stability studies in accordance with ICH Q1A
5. How to submit a DMF to the FDA
- From 2020, submissions will only be accepted in eCTD format.
- It is mandatory to provide XML backbone and Sequence.
- Initial registration requires filing FDA Form 3938.
- The DMF must receive a dedicated DMF number from the FDA.
6. Reference and permission to access DMF
- The API manufacturer can allow the pharmaceutical company to reference the DMF in its product registration application.
- This is done by providing a Letter of Authorization (LOA).
- Only regulatory agencies have access to the entire content of the DMF.
7. Difference between DMF and CEP (in EMA)
In Europe, the alternative or equivalent to the DMF is the CEP (Certificate of Suitability), issued by the EDQM, which simplifies the review and verification of the quality of the API instead of submitting the entire DMF.
8. Important tips for success in preparing a DMF
- Full compliance with GMP principles in API production
- Preparing accurate and scientific documentation, using CTD/eCTD format
- استفاده از نرمافزارهای معتبر تهیه eCTD
- Review by Regulatory Affairs experts before submission
- Keeping DMFs up to date and notifying FDA of significant changes
9. Benefits of having an active DMF
- Increasing the credibility of the API manufacturer in the global market
- Facilitating B2B contracts with pharmaceutical companies
- Saving time and cost of registering products in different markets
- Possibility of entering international projects such as the WHO PQ program
Conclusion
Preparing a DMF for APIs is not only a tool for protecting intellectual property, but also a bridge between the manufacturer and global regulatory agencies. By following standard structures, using appropriate software, and working closely with regulatory teams, the DMF preparation and registration process can be successfully carried out.
